Korean Stock Flows

Celltrion Pharm (KRX: 068760)

셀트리온제약 KOSDAQ Biotech & Pharma 의약품 제조업
Close (Oct 13, 2026)
₩37,550
-1.96%
Market cap
₩2T ($1.3B)
52-week range
₩36,400 – ₩78,300
P/E (FY1 fwd) · P/B · Div yield
36.28 · 3.81 · 0.53%
trailing 42.91 · consensus of analysts

Who is buying Celltrion Pharm?

Between Sep 10, 2026 and Oct 13, 2026 (20 trading sessions), foreign investors net bought ₩0.7bn ($1M) of Celltrion Pharm, the 198th largest foreign net purchase among 1828 KOSDAQ stocks. Institutions net sold ₩9.4bn ($7M) and retail investors net bought ₩8.6bn ($6M) over the same window. Foreigners were net buyers on 8 of the 20 sessions.

Foreign investors hold 4.9% of Celltrion Pharm's listed shares (KRX ownership data as of Oct 13, 2026), up from 4.83% twenty sessions earlier and 3.55% a year ago.

The stock closed at ₩37,550 on Oct 13, 2026: -6.71% over 20 sessions, -35.26% year-to-date, -27.75% over one year. The 52-week range is ₩36,400 – ₩78,300.

At ₩37,550 the stock trades at 36.28× current-fiscal-year consensus earnings. The trailing P/E published by KRX is 42.91×, based on the last completed fiscal year.

Celltrion Pharm share price, last 60 trading days (KRW)
46,613 43,421 40,229 37,037 Jul 13 Aug 26 Oct 13
Daily foreign investor net purchases, last 60 trading days
+3bn +1.5bn -1.5bn -3bn Jul 13 Aug 26 Oct 13
View chart data as a table
Date Close Foreign net Institutions Retail
2026-10-13 ₩37,550 ₩-0.7bn +₩0.3bn +₩0.3bn
2026-10-12 ₩38,300 ₩-0.7bn ₩-0.1bn +₩0.9bn
2026-10-08 ₩38,800 ₩-0.4bn ₩-0.5bn +₩0.9bn
2026-10-07 ₩40,100 +₩0.6bn +₩0.1bn ₩-0.8bn
2026-10-06 ₩39,650 +₩2.2bn +₩0.1bn ₩-2.4bn
2026-10-02 ₩38,400 ₩-1.2bn ₩-2.0bn +₩3.1bn
2026-10-01 ₩39,650 +₩3.0bn +₩0.0bn ₩-3.0bn
2026-09-30 ₩38,100 +₩0.0bn ₩-2.2bn +₩2.2bn
2026-09-29 ₩38,600 ₩-0.6bn ₩-2.5bn +₩3.1bn
2026-09-28 ₩39,350 +₩1.7bn ₩-2.0bn +₩0.3bn
2026-09-23 ₩39,050 +₩0.1bn ₩-0.1bn ₩-0.0bn
2026-09-22 ₩38,800 ₩-0.4bn ₩-0.3bn +₩0.7bn
2026-09-21 ₩39,500 +₩0.4bn ₩-0.0bn ₩-0.4bn
2026-09-18 ₩39,100 ₩-1.9bn +₩0.3bn +₩1.6bn
2026-09-17 ₩39,200 ₩-0.6bn +₩0.4bn +₩0.1bn
2026-09-16 ₩38,800 ₩-0.4bn ₩-0.2bn +₩0.6bn
2026-09-15 ₩39,250 ₩-0.1bn +₩0.3bn ₩-0.2bn
2026-09-14 ₩39,400 +₩0.2bn ₩-0.5bn +₩0.2bn
2026-09-11 ₩39,400 ₩-0.4bn ₩-0.9bn +₩1.3bn
2026-09-10 ₩40,000 ₩-0.2bn +₩0.1bn +₩0.1bn
2026-09-09 ₩40,250 ₩-0.1bn +₩0.0bn +₩0.0bn
2026-09-08 ₩40,000 ₩-0.5bn ₩-0.3bn +₩0.8bn
2026-09-07 ₩40,550 ₩-1.0bn ₩-0.2bn +₩1.2bn
2026-09-04 ₩40,850 ₩-0.8bn +₩0.0bn +₩0.7bn
2026-09-03 ₩40,850 +₩0.0bn ₩-0.5bn +₩0.5bn
2026-09-02 ₩41,150 +₩0.8bn ₩-0.8bn +₩0.0bn
2026-09-01 ₩41,550 +₩0.8bn ₩-0.8bn ₩-0.0bn
2026-08-31 ₩41,700 +₩0.2bn ₩-0.8bn +₩0.6bn
2026-08-28 ₩42,600 +₩0.0bn ₩-0.0bn +₩0.0bn
2026-08-27 ₩42,000 ₩-1.0bn +₩0.2bn +₩0.9bn
2026-08-26 ₩42,550 +₩0.3bn ₩-0.4bn +₩0.2bn
2026-08-25 ₩42,000 ₩-1.1bn +₩0.0bn +₩1.0bn
2026-08-24 ₩42,800 +₩0.9bn +₩0.3bn ₩-1.2bn
2026-08-21 ₩41,550 ₩-1.2bn ₩-0.3bn +₩1.6bn
2026-08-20 ₩42,950 +₩0.8bn +₩0.5bn ₩-1.3bn
2026-08-19 ₩41,150 ₩-0.6bn +₩0.2bn +₩0.4bn
2026-08-18 ₩41,900 ₩-0.8bn ₩-1.4bn +₩2.1bn
2026-08-14 ₩43,950 ₩-0.2bn ₩-0.9bn +₩1.1bn
2026-08-13 ₩44,650 ₩-0.9bn +₩1.8bn ₩-1.0bn
2026-08-12 ₩44,450 ₩-1.1bn +₩0.9bn +₩0.4bn
2026-08-11 ₩46,100 +₩1.2bn ₩-0.7bn ₩-0.5bn
2026-08-10 ₩45,000 ₩-0.2bn +₩1.4bn ₩-1.2bn
2026-08-07 ₩44,200 +₩0.4bn ₩-0.5bn +₩0.0bn
2026-08-06 ₩43,450 +₩0.4bn +₩0.7bn ₩-1.0bn
2026-08-05 ₩42,000 +₩0.4bn ₩-0.7bn +₩0.3bn
2026-08-04 ₩41,700 ₩-0.1bn +₩1.5bn ₩-1.5bn
2026-08-03 ₩40,300 +₩0.6bn ₩-0.1bn ₩-0.5bn
2026-07-31 ₩40,200 +₩1.1bn +₩0.7bn ₩-1.8bn
2026-07-30 ₩38,700 +₩0.5bn ₩-0.1bn ₩-0.4bn
2026-07-29 ₩38,500 ₩-2.2bn +₩2.4bn ₩-0.3bn
2026-07-28 ₩39,900 ₩-0.5bn +₩0.6bn ₩-0.1bn
2026-07-27 ₩40,850 ₩-1.1bn +₩1.1bn ₩-0.0bn
2026-07-24 ₩40,400 +₩2.4bn ₩-0.1bn ₩-2.3bn
2026-07-23 ₩39,050 ₩-0.0bn +₩0.9bn ₩-0.9bn
2026-07-22 ₩38,000 +₩0.3bn ₩-0.1bn ₩-0.2bn
2026-07-21 ₩38,250 +₩0.5bn +₩0.5bn ₩-1.0bn
2026-07-20 ₩38,250 ₩-1.0bn +₩0.3bn +₩0.7bn
2026-07-16 ₩39,800 +₩0.4bn ₩-0.1bn ₩-0.3bn
2026-07-15 ₩40,100 ₩-0.1bn ₩-0.1bn +₩0.2bn
2026-07-14 ₩39,700 ₩-0.7bn +₩1.1bn ₩-0.4bn
2026-07-13 ₩40,250 ₩-0.4bn ₩-0.3bn +₩0.7bn

Investor flows summary

Window Foreign (USD) Institutions Retail
1 day ₩-0.7bn $-1M +₩0.3bn +₩0.3bn
5 days +₩1.1bn +$1M ₩-0.1bn ₩-1.0bn
20 days +₩0.7bn +$1M ₩-9.4bn +₩8.6bn

Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.

Frequently asked questions

Are foreign investors buying Celltrion Pharm stock?

Over the last 5 sessions foreign investors net bought ₩1.1bn ($1M) of Celltrion Pharm; over 60 sessions they net sold ₩2.3bn ($2M); since Jan 1, 2026 they net bought ₩29.8bn ($22M). Over 20 sessions the stock is the 198th largest foreign net purchase among 1828 KOSDAQ stocks.

How much of Celltrion Pharm do foreign investors own?

Foreign investors own 4.9% of Celltrion Pharm's shares as of Oct 13, 2026, versus 3.55% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.

Who is on the other side — institutions or retail investors?

Over 20 sessions institutions net sold ₩9.4bn ($7M) and retail investors net bought ₩8.6bn ($6M) of Celltrion Pharm. Foreign buying is being met mainly by institutional selling.

Is Celltrion Pharm listed on KOSPI or KOSDAQ?

Celltrion Pharm (셀트리온제약) trades on KOSDAQ under KRX code 068760 in the Biotech & Pharma group, with a market capitalization of ₩2T ($1.3B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.

Annual financials

Fiscal year Revenue YoY Operating profit Net income
2023 ₩389bn ($292M) – ₩36bn ($27M) ₩21bn ($16M)
2024 ₩478bn ($358M) +22.90% ₩37bn ($28M) ₩22bn ($16M)
2025 ₩536bn ($402M) +12.30% ₩56bn ($42M) ₩39bn ($29M)

Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1333.09/$) for reference only.

← All foreign investor flows